brolucizumab


( Last Updated : June 2, 2022)
Generic Name:
brolucizumab
Project Status:
Pending
Therapeutic Area:
Diabetic macular edema
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Beovu
Project Line:
Reimbursement Review
Project Number:
SR0747-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
The treatment of diabetic macular edema (DME).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
The treatment of diabetic macular edema (DME).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.